Quotes 5-day view Delayed Nasdaq
09/21/2020
09/22/2020
09/23/2020
09/24/2020
09/25/2020
Date
64.21(c)
63.4(c)
63.09(c)
62.25(c)
61.98 Last
8 575 185
7 228 235
8 520 245
9 004 618
2 296 203 Volume
-1.29% -1.26% -0.49% -1.33% -0.43% Change
Sales 2020
24 281 M - -
Net income 2020
2 423 M - -
Net Debt 2020
3 137 M - -
P/E ratio 2020
34,0x
Yield 2020
4,33%
Sales 2021
24 050 M - -
Net income 2021
7 400 M - -
Net Debt 2021
1 353 M - -
P/E ratio 2021
10,2x
Yield 2021
4,61%
Capitalization
78 044 M 78 044 M -
EV / Sales 2020
3,34x
EV / Sales 2021
3,30x
Nbr of Employees
11 800
Free-Float
99,6%
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.5%): especially royalties and...
Notations Surperformance© of Gilead Sciences, Inc.
Trading Rating : Investor Rating :
All news about GILEAD SCIENCES, INC.
News in other languages on GILEAD SCIENCES, INC.
Analyst Recommendations on GILEAD SCIENCES, INC.
GILEAD SCIENCES - 02/03
Volatility should make a big comeback
BUY
Chart GILEAD SCIENCES, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends GILEAD SCIENCES, INC.
Short Term Mid-Term Long Term Trends Bearish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
29
Average target price
78,79 $
Last Close Price
62,25 $
Spread / Highest target
68,7%
Spread / Average Target
26,6%
Spread / Lowest Target
-0,40%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
